GLP-1SG

GLP-1SG is a long-acting GLP-1 receptor agonist featuring a C-18 fatty di-acid chain that enables albumin binding and extends its half-life to approximately 7 days. It is one of the most extensively studied incretin analogs and has become a benchmark compound in metabolic and cardiovascular research.

GLP-1SG binds to the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion and suppressing glucagon release. It delays gastric emptying and activates GLP-1R-expressing neurons in the hypothalamus to reduce appetite. The C-18 fatty acid modification enables non-covalent albumin binding, dramatically extending circulation half-life. This compound also demonstrates anti-inflammatory effects on vascular endothelium and has shown cardioprotective signals in large-scale research.

Research includes GLP-1R signaling pathway studies, dose-response insulin secretion assays, hypothalamic appetite center neuroscience, cardiovascular protection models, hepatic steatosis research, comparative pharmacology against other GLP-1 receptor agonists and dual-agonist compounds, and long-acting peptide pharmacokinetics.